The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy in patients with locally advanced pancreatic cancer.
Davendra Sohal
No relevant relationships to disclose
James M. Metz
No relevant relationships to disclose
Weijing Sun
No relevant relationships to disclose
Kathleen Harlacker
No relevant relationships to disclose
Bruce J. Giantonio
No relevant relationships to disclose
Ernest F. Rosato
No relevant relationships to disclose
Gregory Ginsberg
No relevant relationships to disclose
Michael Kochman
No relevant relationships to disclose
Ursina R. Teitelbaum
No relevant relationships to disclose
Colleen Redlinger
No relevant relationships to disclose
Michael D Feldman
No relevant relationships to disclose
Jeffrey A. Drebin
No relevant relationships to disclose
Peter James O'Dwyer
No relevant relationships to disclose